U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197112) titled 'Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy' on Sept. 19.
Brief Summary: An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line therapy.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Acute Graft Versus Host Disease Grade II-IV
Acute Graft vs Host Disease
Intervention:
DRUG: Gecacitinib
Administer 50 mg twice daily for a minimum of 28 days.
Recruitme...